Here we go again! Which girl is your favorite? Tila Tequila doesn’t count cause she’s a pro lol!
| Click to vote for me! |
Here we go again! Which girl is your favorite? Tila Tequila doesn’t count cause she’s a pro lol!
| Click to vote for me! |
Don’t forget that this weekend these girls want to meet you! Then empty your wallet and hook up with another guy! BITCHES! LOL!
| Click to vote for me! |
Elisha Cuthbert was in The Girl Next Door as every teen guy’s sexy dream girl. She really knows how to work it!
| Click to vote for me! |
Do hot girls make the world go round? I know these girls are helping me in more ways than one haha!
| Click to vote for me! |
« Subject Safety And Efficacy Of Sunitinib In An Expanded-access Trial Of Metastatic Renal Cell Carcinoma (mrcc) | Main | Comments Requested Controversial Anemia Drug Doesn’t Cut Need For Transfusions (healthday) »
By admin2 | May 31, 2008
GlaxoSmithKline (GSK) announced that the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a revised positive opinion confirming the positive benefit-risk profile for Tyverb® (lapatinib), GSK’s new oral treatment for breast cancer. The positive opinion recommends grant of a conditional marketing authorisation.The CHMP previously issued a positive opinion for lapatinib in December 2007.
(Link)
Topics: Cancer |